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Brain metastasis (B-Met) from melanoma remains mostly incurable and the main cause
of death from the disease. Early stage clinical trials and case studies show some promise
for targeted therapies in the treatment of melanoma B-Met. However, the progression-
free survival for currently available therapies, although significantly improved, is still very
short. The development of new potent agents to eradicate melanoma B-Met relies on the
elucidation of the molecular mechanisms that allow melanoma cells to reach and colonize
the brain. The discovery of such mechanisms depends heavily on pre-clinical models that
enable the testing of candidate factors and therapeutic agents in vivo. In this review we
summarize the effects of available targeted therapies on melanoma B-Met in the clinic. We
provide an overview of existing pre-clinical models to study the disease and discuss specific
molecules and mechanisms reported to modulate different aspects of melanoma B-Met
and finally, by integrating both clinical and basic data, we summarize both opportunities
and challenges currently presented to researchers in the field.
Keywords: melanoma brain metastasis, melanoma, brain metastasis, brain tropism, therapy-related,
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BRAIN METASTASIS FROMMELANOMA – A CLINICAL
CHALLENGE
Brain metastasis (B-Met) occurs in 5–15% of all melanoma
patients and is the cause of death in half of metastatic melanoma
patients (Johnson and Young, 1996; Sampson et al., 1998; Davies
et al., 2011). Disseminated melanoma cells are able to extravasate
through the highly restrictive blood brain barrier (BBB) and
mostly inhabit the parenchyma, with less frequent leptomeningeal
or cerebral spinal fluid (CSF) metastasis.
Currently, treatments for B-Met are determined by their num-
ber, anatomic location, surgical risk, systemic disease burden, and
leptomeningeal involvement. Patients with a limited number of
resectable B-Met may undergo surgical resection or stereotac-
tic radiosurgery. These procedures appear to prolong survival
in a subset of patients as reported by retrospective analyses
(Lonser et al., 2011; Salvati et al., 2012). Patients with inopera-
ble disease are usually treated with whole-brain radiation ther-
apy (WBRT) or chemotherapy such as temozolomide (Eichler
and Loeffler, 2007). Response rates to single-agent chemother-
apy are <10%, and treatment simply attempts to slow disease
progression (Ewend et al., 2001; Agarwala et al., 2004; Eichler
and Loeffler, 2007). It is becoming clearer that the genetic back-
ground of a certain patient (i.e., germline mutations) or a tumor
should dictate its treatment regimen, and that targeted therapy
against these tumor-specific alterations (if available) may be more
efficacious. In the case of familial melanoma, germline inactivat-
ing mutations in the CDKN2A/B locus (mainly p16 and p14)
are common (Straume et al., 2002; Gast et al., 2010), leading to
aberrant CDK4/cyclin D activity that drives melanoma cell cycle
progression. It is plausible that germline mutations contribute to
tumor progression by affecting non-melanocytic tissues as well
and by that, affecting metastatic potential. For example, certain
mutations may affect blood vessels permeability, predisposing
patients to increased metastatic spread. The systemic effects of
prevalent germline mutations in cancer patients may prove rele-
vant for the development of future tailored personalized medicine.
On the other hand, prevalent somatic mutations in melanoma
are the subject of intense studies. More than 50% of metasta-
tic melanoma tumors harbor an activating mutation in codon
600 of the BRAF gene (V600E or, to a lesser extent, V600K)
(Davies et al., 2002). Recently, selective BRAF inhibitors such
as PLX4032 (vemurafenib) and GSK2118436 (dabrafenib) have
shown clinical efficacy in BRAF mutant metastatic melanoma
patients (Flaherty et al., 2010) with significant tumor regression in
approximately 60% of patients (Flaherty et al., 2010). Clinical tri-
als using BRAF inhibitors to treat patients with melanoma B-Met
were initiated recently with promising results despite the small
sample size. A phase I study tested the effects of dabrafenib in
10 patients with untreated and asymptomatic B-Met. Nine of ten
patients displayed reductions in size of brain lesions (Falchook
et al., 2012). In addition, an ongoing phase II trial is designed
to assess the efficacy, pharmacokinetics, safety, and tolerability
of dabrafenib administered to a large cohort of subjects with
BRAFV600E/K mutation-positive B-Met (ClinicalTrials.gov Iden-
tifier: NCT01266967). However, resistance to the BRAF inhibitor
is already evident. In part, this phenomenon is attributed to addic-
tion or functional redundancy within the MAPK pathway, which
likely buffers the impact of a single gene/target modification on the
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malignant process (Johannessen et al., 2010; Nazarian et al., 2010).
Moreover, Poulikakos et al. (2011) have identified an additional
resistance mechanism in which a splicing variant of mutatedBRAF
that lacks the region encompassing the RAS-binding domain,
showed enhanced dimerization in vemurafenib-treated cells.
Another promising, potent agent used lately in late stage
melanoma patients is ipilimumab, a monoclonal antibody against
the CTLA-4 molecule expressed mainly on regulatory T cells. This
antibody blocks CTLA-4 signaling that acts as an immune check-
point to inhibit T-cell activation [reviewed in (Melero et al., 2007)].
The use of ipilimumab improved overall survival with 10.9%
of patients exhibiting complete response, with mostly reversible
adverse effects (Hodi et al., 2010) in around 15–20% of patients.
Recent reports have suggested that ipilimumab can promote the
regression of melanoma B-Met. Case studies reported that ipil-
imumab significantly benefited individuals with central nervous
system (CNS) metastasis (Hodi et al., 2008; Schartz et al., 2010). In
a phase II trial of 72 patients with B-Met treated with ipilimumab,
18% of participants that had asymptomatic B-Met and were not
treated previously with steroids achieved disease control (partial
response or stable disease). The study revealed long-term survival
rates comparable to those seen in patients without B-Met, with
approximately one-third of patients alive at 12 months. Patients
treated with steroids did not show similar responses (Margolin
et al., 2012).
The progression-free survival, for both ipilimumab and
dabrafenib/vemurafenib-treated patients, although significantly
improved, is still very short. Nevertheless, these studies showing
unprecedented efficacy against melanoma B-Met exemplify that
targeted therapy could be key to the eradication of these highly
aggressive metastases.
WHY DO MELANOMAS METASTASIZE TO THE BRAIN?
The concept that metastases arising in different locations in the
body carry site-specific characteristics that facilitate tissue colo-
nization is a subject of intense research in various types of cancers.
Several studies over the past few years were dedicated to elucidate
the molecular and cellular basis of melanoma B-Met, using both
experimental and pre-clinical models for this condition.
Interestingly, when melanoma becomes metastatic, it has the
highest risk among all tumors for B-Met development with 44–
64% of patients (Davies et al., 2011). Moreover, in melanoma
patients, a higher proportion of B-Met represent the only site of
metastatic disease compared to other solid tumors that frequently
metastasize to the brain (Thompson et al., 2004). Strikingly, in a
retrospective analysis of more than 2000 melanoma patients our
group showed that 36% of melanoma B-Met represent the first
and isolated site of metastasis (Ma et al., 2012). Primary tumors
of patients from this subgroup displayed distinct clinicopatholog-
ical features with thinner (mostly stage 1), non-mitotic lesions.
Another study by our group of 900 primary melanoma patients
showed that location of the primary tumor on the head and neck
was an independent predictor of B-Met (Zakrzewski et al., 2011).
However, the correlation between anatomical site and B-Met does
not hold when analyzing only tumors with B-Met as first isolated
site (Ma et al., 2012), suggesting that the predilection to metasta-
size to the brain is already molecularly “encoded” in some primary
melanomas that represent a distinct clinicopathological and pos-
sibly molecular entity. It was hypothesized that the high CNS
involvement of melanoma may be due to a “homing” effect, since
melanocytes and neuronal subpopulations such as glial cells and
sensory neurons share a common neural crest progenitor (Her-
lyn et al., 2000). However, this hypothesis has not yet been yet
thoroughly investigated experimentally.
From a molecular point of view it is imperative to ask whether a
specific set of conditions need to occur in order for melanoma cells
to seed and proliferate in a certain tissue. Multiple studies, mainly
in the context of breast cancer, demonstrated how metastasis to
different sites involves unique programs that facilitate tumor cell
seeding and proliferation within the myriad of specialized cell
types and extracellular matrices of the foreign tissue (Padua et al.,
2008; Bos et al., 2009; Zhang et al., 2009a). Organ specificity can
also be achieved by differential expression of molecules on resident
cells of the invaded tissue. For example, the adhesion molecule
Lu-ECAM-1 was reported to be specifically expressed on distinct
branches of lung blood vessels, facilitating the arrest and binding
of melanoma cells with higher affinity to it (Zhu et al., 1991). As
for tropism of cancer cells to the brain, a study by Weiss (1992)
estimated that the arrival of 66% of hematogenous B-Met may
be explained by blood circulation while the remaining metastases
may reflect site specificity.
IN VIVO MODELS OF MELANOMA BRAIN METASTASIS
Several groups have reported the development and use of in vivo
models of melanoma B-Met (Fujimaki et al., 1996;Yano et al., 2000;
Küsters et al., 2003; Xie et al., 2006; Huang et al., 2008; Zhang et al.,
2009b) (summarized in Table 1). Nonetheless, there are consid-
erable shortcomings in most of them. The ‘spontaneous’ B-Met
model induced through subcutaneous transplantation of tumor
cells in the flank allows sufficient time for primary tumor cells to
disseminate and establish distant metastases (Cruz-Munoz et al.,
2008). In such model, a melanoma cell line was used to gener-
ate a systemic metastatic disease in NOD/SCID mice. Mice were
then subjected to a metronomic chemotherapy and surviving mice
developed spontaneous B-Met. Cell lines established from B-Met
were then proven to metastasize to the brain parenchyma effi-
ciently and with shorter latency. This model recreates the multiple
sequential steps that are associated with the metastatic cascade,
making it closely resembled to the clinical disease. However, the
long latency period needed for metastatic disease in the brain
to become evident, the relatively low incidence, and the limited
number of syngeneic and xenograft spontaneous B-Met models
available makes this approach less appealing when compared to
other models.
Mouse models in which melanoma B-Met is induced through
direct injection of cancer cells into the circulation, known as
‘experimental’ models, do not reflect the complete series of events
involved in the metastatic process. Nevertheless, they allow for
both controlled delivery of cancer cells and a short time for
metastatic disease to manifest. These models are particularly suit-
able to study later stages of B-Met such as seeding and tissue
colonization. These characteristics, along with the availability of
many well-characterized cell lines, make these models attractive
to study B-Met in pre-clinical settings. Notably, nearly all of the
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Table 1 | In vivo models of melanoma brain metastasis.
Model Technique Advantages Limitations
Spontaneous brain
metastasis
(Cruz-Munoz et al.,
2008; Cruz-Muñoz
et al., 2012)
Subcutaneous implementation of
pre-selected clones followed by tumor
resection. Metastatic disease in the
brain is allowed to occur spontaneously
from metastasizing cells leaving the
subcutaneous implementation site
Recreates the multiple sequential steps that are
associated with the metastatic cascade, making
it closely resembled to the clinical disease
Suitable for pre-clinical testing of adjuvant
therapies
Relatively low throughput
Very long latency period needed for
metastatic disease in the brain to
become evident
Relatively low incidence
Limited number of available
pre-selected cell lines to be used
Intra-carotid injection
(Fujimaki et al., 1996;
Yano et al., 2000; Xie
et al., 2006; Huang
et al., 2008; Zhang
et al., 2009b)
Cells are injected into the internal
carotid artery
Allows for controlled delivery of cancer cells
Offers a short time for metastatic disease to
manifest
Availability of many well-characterized cell lines
Technically challenging
Does not reflect the complete
series of events involved in the
metastatic process
Extremely short latency between
tumor induction and mortality
Mostly leptomeningeal metastases
are formed
Intra-cardiac
injection (Izraely
et al., 2012; Tekle
et al., 2012; Morsi
et al., 2013;
Sundstrøm et al.,
2013 )
Cells are injected into the left ventricle
of the heart
Relatively high-throughput
Recapitulates most relevant stages of the
metastatic spread to the brain
Technically feasible
May produce parenchymal lesions
Reasonable latency between inoculation to
appearance of brain metastasis – may be used
for pre-clinical testing of adjuvant therapies
Does not reflect the complete
series of events involved in the
metastatic process
Limited number of available
pre-selected cell lines to be used
Injection into chick
embryo (Busch
et al., 2012)
Cells are injected into the
rhombencephalic brain vesicle of a
2-day-chick embryo. Two to three days
post-injection tumor formation is
studied
Fast
Controlled delivery of cells
May be used with multiple cell lines
Physiological relevance is not yet
established
Limited to study certain processes
such as extravasation and local
invasion
experimental melanoma B-Met studies use internal carotid artery
injections (Fujimaki et al., 1996; Yano et al., 2000; Küsters et al.,
2003; Xie et al., 2006; Huang et al., 2008; Zhang et al., 2009b).
This method of tumor induction, although still a commonly used
methodology, is time consuming and requires certain level of sur-
gical expertise. In addition, this route of injection proved to be
“artificially” invasive, with extremely short latency between tumor
induction and mortality, putting its physiological relevance in
question. Moreover, the B16 syngeneic cell line used vastly in this
model develops exclusively leptomeningeal metastasis, as opposed
to the more prevalent parenchymal dissemination. This consider-
able shortcoming renders the B16 a less clinically relevant model
with low translational potential.
Recently, intra-cardiac injection has been established as a less
invasive and less technically demanding route of B-Met induc-
tion. In these studies, human cells are injected directly into the
left ventricle of the heart of immuno-deficient mice to develop
a more clinically relevant in vivo model. Following this method-
ology, human melanoma cell lines directly injected in athymic
nude (Izraely et al., 2012) or Balb/c mice (Tekle et al., 2012) suc-
cessfully developed parenchymal lesions. A new model developed
recently by Sundstrøm et al. (2013) utilized intra-cardiac injection
of melanoma cells labeled with superparamagnetic iron oxide
nanoparticles (SPIONs). These cells were effectively visualized by
magnetic resonance imaging (MRI) followed by automated analy-
sis. Our group combined ultrasound-guided intra-cardiac injec-
tion of melanoma cells as a minimally invasive, high-throughput
method of induction, with MRI-assisted tumor segmentation,
3D reconstruction and quantitative volumetric analysis, to pre-
cisely map and measure parenchymal B-Mets (Morsi et al., 2013).
This approach takes advantage of the paramagnetic nature of
melanin, which renders a signal brightening endogenous effect
in tracer-free T1-weighted MRI (Isiklar et al., 1995). Importantly,
the metastatic pattern observed in both studies resembled the one
seen in patients and was highly reproducible. This type of in-
depth characterization of the growth pattern of B-Met lesions
developing within in vivo models, using various imaging tech-
niques, will allow to faithfully assess melanoma brain tropism,
seeding and adaptation, study the molecular mechanisms that con-
trol these processes, and may be used to test potential therapeutic
agents.
Lately, a study by Busch et al., made use of the chick embryo
model to study melanoma B-Met. Melanoma cell lines were
injected into the rhombencephalic brain vesicle of the 2-day-chick
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embryo. Two to three days post-injection, tumor formation was
studied in serial paraffin sections (Busch et al., 2012). The chick
embryo model is inherently limiting in studying crucial stages of
melanoma dissemination to the brain but can be exploited to study
early phases such as extravasation and local invasion in the brain.
HOW DO MELANOMAS REACH AND ADAPT TO THE BRAIN
MICROENVIRONMENT?
The exact sequence of events required by tumor cells for suc-
cessful colonization of the brain remains obscure. Kienast and
colleagues used multiphoton laser scanning real-time microscopy
to follow single steps of B-Met formation. Their innovative exper-
imental system enabled them to follow melanoma cells injected
into the internal carotid artery arrest at vascular branch points,
extravasate early, remain in close and persistent contacts to
microvessels, and co-opt the vessel for nutrients. This final step
was unique for melanomas that, as opposed to lung cancer-
derived cells, did not induce early angiogenesis (Kienast et al.,
2010). This particular finding is intriguing and suggests that B-Met
originating from different tumor types possess distinct molecu-
lar properties and may respond differently to certain therapies
and thus, should not necessarily be treated uniformly as one
entity.
The multistage process of metastatic spread to the brain
requires the involvement and integration of multiple biological
events. In vitro and in vivo models studying the nature of the alter-
ations required for melanoma cells’ tropism to the brain revealed
a number of effectors to mediate different aspects of that process.
Interestingly, most reports do not claim the alterations found to
be exclusive of B-Met. While those are relevant for the elucidation
of the mechanisms that govern melanoma B-Met, the discovery
of site-specific molecular alterations may be key for the develop-
ment of potent, site-specific therapy. This approach may be highly
beneficial for patients, especially since current data clearly point
to a model in which melanoma B-Met are not always a late stage
metastatic disease but may also be a unique entity with possi-
bly distinct molecular profile. Below we summarize some of the
molecular factors implicated so far in melanoma B-Met models
(depicted in Figure 1).
JAK-STAT
The JAK-STAT pathway, that promotes survival, growth, and
angiogenesis, was reported to increase melanoma B-Met mainly
via STAT3 activation by phosphorylation, or downregulation of
its inhibitor SOCS-1 (Xie et al., 2006; Huang et al., 2008). The
main effects observed in both studies were increased expres-
sion of MMP-2, bFGF, and VEGF, possibly supporting melanoma
cell invasion and angiogenesis. Importantly, STAT3 activation
and consequential effects were a more general pro-metastatic
phenomenon, not restricted to B-Met. In fact, a recent study
showed that melanoma lung metastases exhibited the highest
level of p-STAT3 expression and that p-STAT3 expression was
not associated with an increased risk of developing B-Met or
time to B-Met (Lee et al., 2012). It still remains to be deter-
mined whether the effects of SOCS-1 are more specific to B-
Met, but since its main downstream target reported in the
study was STAT3, a brain metastatic-specific mechanism seems
unlikely.
FIGURE 1 | Molecular determinants of melanoma brain metastasis.
Molecular alterations may occur on all consecutive steps that support
the metastatic process of melanoma cells to the brain. Alterations in
specific factors may support processes at the primary tumor site and
endow a subset of cells with the ability to reach the brain (represented
by green cells). Other factors may direct migration to the brain via
chemotaxis, or promote adhesion and extravasation through the BBB.
Lastly, inside the brain, other factors facilitate several processes that
allow the successful colonization of the tissue such as vessel co-option
(A), angiogenesis (B), seeding (C), growth (D), survival (E), or
invasiveness (F). Although not yet demonstrated for melanoma, it is
possible that metastatic spread to the brain may also originate from
other visceral metastatic sites such as the lung or the liver
(“metastasis of metastasis”).
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HEPARANASE
The enzyme Heparanase (HPSE) degrades heparan sulfate chains
of proteoglycans that are known to have multiple functions includ-
ing maintaining capillaries support or retaining soluble factors
(e.g., chemokines). Using a brain slice model it was shown that
higher HPSE levels lead to increased invasion of the brain, that
was repressed when specific HPSE inhibitors were used (Murry
et al., 2006). In support of the role of HPSE in promoting B-
Met is a recent study that reported miR-1258 to be a suppressor
of breast cancer B-Met through the direct targeting of HPSE
(Zhang et al., 2011). Since HPSE is a potent pro-tumorigenic
and pro-metastatic agent, its effects might not be confined to
brain-specific processes. Still, HPSE role could be more evident
in B-Met models and patients’ samples since its activity is essential
for the successful extravasation of the blood-borne melanoma
metastasis through the heparan sulfate-rich endothelial cell layer.
Furthermore, co-incubation of astrocytes with melanoma brain
metastatic cells resulted in elevated HPSE activity and markedly
increased invasive capacity in vitro (Marchetti et al., 2000). This
further supports brain-specific activity for this enzyme.
ENDOTHELIN RECEPTOR B
A recent study has implicated Endothelin Receptor B (EDNRB) as a
factor that potentially influences brain metastatic potential. Using
a pre-clinical model of melanoma B-Met developed by the same
group (Cruz-Munoz et al., 2008), the authors showed that EDNRB
overexpression enhanced overall metastatic disease, and increased
the incidence of spontaneous B-Met. The study showed that the
interaction of EDNRB with its ligands caused increased intracra-
nial melanoma growth. Therapeutic treatment by an EDNRB-
specific inhibitor translated into improved outcome in mice. This
study implicates a protein critical for melanocyte biology in pro-
moting melanoma metastatic potential in general and B-Met in
particular (Cruz-Muñoz et al., 2012). Although the pro-metastatic
effects were not exclusive to the brain, the authors postulate that
the high levels of EDNRB ligands in the brain relative to other
organs may explain the overall increased growth within the brain
and the increased frequency of B-Met in this study. Importantly,
endothelin 3 levels are also high in lung tissue and may be respon-
sible for the increased lung metastasis frequency when EDNRB was
ectopically expressed (Fagan et al., 2001). These results are exciting
since they exemplify how melanoma metastatic cells are affected
by surrounding specific microenvironmental ligands and utilize
them for their growth. The successful therapeutic aspect of this
study highlights EDNRB as a potential druggable target. Interest-
ingly, EDNRB overexpression was ectopically induced within the
implanted tumor in the flank where endothelins are not abundant.
Still, EDNRB overexpressing cells metastasized more frequently to
the brain. This points to a model in which EDNRB generally facil-
itates metastatic spread, but its effects are exacerbated in the brain,
where its ligands are abundant.
BCL2A1
A second factor implicated in the same study is the anti-apoptotic
protein BCL2A1, which did not affect the incidence of B-Met
but facilitated intracranial tumor growth, possibly by enhanc-
ing cell survival. Since cells were injected intra-cranially in those
experiments, this finding needs to be further investigated for its
physiological relevance (Cruz-Muñoz et al., 2012).
CONNEXIN 26
Connexins have been lately shown to mediate early events in brain
colonization using transparent zebrafish and chicken embryo
models of B-Met. One study showed that melanoma cells utilize
the gap junction protein Connexin 26 (Cx26) to initiate B-Met for-
mation in association with the vasculature. Cx26 silencing or phar-
macological inhibition of connexins blocked cell extravasation and
blood vessel co-option (Stoletov et al., 2013). The idea that specific
connexins mediate cancer metastasis to the brain by increasing
gap junction communication with the BBB is intriguing, partic-
ularly in the context of previous observations highlighting vessel
co-option among the initial steps of brain colonization unique
to melanoma (Kienast et al., 2010). Interestingly, a study by Lin
et al., reported that activated astrocytes surrounding melanoma
B-Met protect them from chemotherapeutic drugs. This chemo-
protection was dependent on physical contact and gap junctional
communication between astrocytes and tumor cells (Lin et al.,
2010). It will be interesting to examine whether the specific silenc-
ing of Cx26 will be sufficient to eliminate these chemoprotective
effects.
CCR4
The expression of the chemokine receptor CCR4 was found signif-
icantly higher in one melanoma brain metastatic variant compared
to the corresponding tumor implanted in the flank (Izraely et al.,
2010). The same group has reported that brain-derived soluble
factors upregulate the expression of CCR4 in both cutaneous and
brain-metastasizing melanoma cells and enhance the migration
of the latter, but not that of the cutaneous variants (Klein et al.,
2012). These findings support the hypothesis that some alterations
may occur early at the primary tumor site where certain clones
express molecules that promote spread of melanoma cells to the
brain. One can postulate that CCR4 ligands secreted from the brain
interact with the CCR4-positive melanoma cells and attract them
to the brain. This kind of directed migration was reported previ-
ously for breast cancer cells overexpressing CXCR4 that facilitated
their transmigration through the brain endothelial cells (Lee et al.,
2004).
TGFβ2
Overexpression of TGFβ2 in mouse melanoma cells increased their
ability to seed in the brain parenchyma, suggesting a role for this
pathway in determining site specificity in the brain microenviron-
ment (Zhang et al., 2009b). This study illustrates how specific fac-
tors may be crucial for B-Met growth and potentially be exploited
therapeutically to diminish successful seeding.
miR-146a
MicroRNAs (miRs) have demonstrated to play critical roles in
cancer metastasis including melanoma [reviewed in (Segura et al.,
2012)]. miRs emerge as optimal candidates to regulate such a com-
plex and multi-layered process as the metastatic dissemination
within the brain due to their ability to concomitantly control mul-
tiple targets and thus impact various molecular processes. A recent
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study found miR-146a to be nearly undetectable in melanoma cells
selected to metastasize to brain relative to their parental counter-
parts. Overexpression of miR-146a suppressed the migratory and
invasive capacity of those cells possibly by targeting hnRNPC and
increasing β-catenin (Hwang et al., 2012). While the clinical rel-
evance of this finding needs to be further elucidated, ongoing
studies focusing on the potential roles of miRNAs in the modula-
tion of melanoma B-Met might provide a deeper understanding
of the critical pathways that drive or support this condition.
BBB DISRUPTORS
Since melanoma B-Mets are blood-borne, cells must extravasate
through the highly restrictive BBB. Thus, the integrity of the BBB
is essential for the prevention of metastatic infiltration. An in vitro
model of the BBB demonstrated how melanoma cells are able to
penetrate the BBB disrupting major tight junctions molecules such
as ZO-1 and Claudin-5, and reducing transendothelial electrical
resistance (TEER), an indicator of junctional integrity (Fazakas
et al., 2011; reviewed in Wilhelm et al., 2011). The mechanism by
which melanoma cells induce endothelial cells junctional degra-
dation is still unclear but the ability of supernatants of melanoma
cells to generate similar effects points to the involvement of
secreted soluble factors such as proteolytic enzymes mentioned
above.
The development and use of models to study melanoma B-Met
is yielding potential candidates as regulators of B-Met. However,
the physiological relevance of those factors to human disease
should be further confirmed to conclusively establish their clinical
impact.
CHALLENGES AND OPPORTUNITIES
In recent years conventional therapeutic regimens are clearing the
way for tailored, patient-specific therapy. This approach is aimed
to maximize responsiveness to treatment based on the tumor’s
genetics while indirectly reducing side effects caused by the admin-
istration of ineffective treatments, and sparing the normal cells of
the body that do not harbor the same genetic alteration. Some
case reports and early phase clinical trials show promise for tar-
geted therapies in the treatment of melanoma patients with B-Met.
This is encouraging, especially since those patients have been, thus
far, systematically excluded from most clinical trials. Still, current
therapies improve overall survival only marginally and there is a
pressing need for B-Met-specific treatments. The notion that the
predilection to metastasize to the brain is present in melanoma
cells possibly already at the time of primary diagnosis provides a
unique opportunity to use specific adjuvant therapy to prevent or
reduce metastatic dissemination in patients at higher risk of devel-
oping B-Met. The characterization of mechanisms that endow
cells with brain-specific tropism and colonization is incipient and
ought to be thoroughly investigated. This might add another layer
of specificity to the treatment regimens patients are offered based
on their site of metastatic dissemination.
The development of in vitro and in vivo models of melanoma B-
Met to discover the molecular mechanisms underlying melanoma
B-Met has progressed significantly. Molecular alterations most
often seen in melanoma B-Met are typically those resulting in:
(i) increased BBB permeability (via junctional, adhesion, and pro-
teolytic factors), (ii) increased tropism to brain microenvironment
(via chemokine and cytokines signaling), (iii) enhanced survival
in the brain (through modulation of pro-proliferative and anti-
apoptotic factors). Nevertheless, novel imaging techniques such
as multiphoton microscopy may provide better resolution, real-
time assessment of the metastatic process in the brain and its
modulation by certain molecules or therapies. Data accumulated
from current and future experimental and pre-clinical models
of melanoma B-Met should be used to develop new site-specific
therapies to efficiently target melanoma B-Met. One can envi-
sion therapies focusing on preventing the arrival and seeding of
melanoma cells to the brain by blocking certain cell surface recep-
tors or secretion of specific proteolytic enzymes. Targeting the
specific interactions of melanoma B-Met with resident cells in the
brain parenchyma is another good example of future site-specific
therapy that may be developed relying on data arising from pre-
clinical models. The outstanding question of whether melanoma
B-Met is indeed a separate molecular entity remains mostly unan-
swered. In that regard, generalized use of next-generation deep
sequencing of clinical specimens should provide new insights and
might alter dramatically our perception of this disease.
REFERENCES
Agarwala, S. S., Kirkwood, J.
M., Gore, M., Dreno, B.,
Thatcher, N., Czarnetski, B., et
al. (2004). Temozolomide for
the treatment of brain metas-
tases associated with metastatic
melanoma: a phase II study.
J. Clin. Oncol. 22, 2101–2107.
doi:10.1200/JCO.2004.11.044
Bos, P. D., Zhang, X. H., Nadal, C.,
Shu, W., Gomis, R. R., Nguyen,
D. X., et al. (2009). Genes that
mediate breast cancer metastasis to
the brain. Nature 459, 1005–1009.
doi:10.1038/nature08021
Busch, C., Krochmann, J., and Drews,
U. (2012). Human melanoma cells
in the rhombencephalon of the
chick embryo: a novel model for
brain metastasis. Exp. Dermatol. 21,
944–947. doi:10.1111/exd.12041
Cruz-Muñoz, W., Jaramillo, M. L.,
Man, S., Xu, P., Banville, M.,
Collins, C., et al. (2012). Roles for
endothelin receptor B and BCL2A1
in spontaneous CNS metastasis
of melanoma. Cancer Res. 72,
4909–4919. doi:10.1158/0008-
5472.CAN-12-2194
Cruz-Munoz, W., Man, S., Xu, P., and
Kerbel, R. S. (2008). Development of
a preclinical model of spontaneous
human melanoma central ner-
vous system metastasis. Cancer Res.
68, 4500–4505. doi:10.1158/0008-
5472.CAN-08-0041
Davies, H., Bignell, G. R., Cox, C.,
Stephens, P., Edkins, S., Clegg, S., et
al. (2002). Mutations of the BRAF
gene in human cancer. Nature 417,
949–954. doi:10.1038/nature00766
Davies, M. A., Liu, P., McIntyre, S., Kim,
K. B., Papadopoulos, N., Hwu, W.
J., et al. (2011). Prognostic factors
for survival in melanoma patients
with brain metastases. Cancer 117,
1687–1696. doi:10.1002/cncr.25634
Eichler, A. F., and Loeffler, J.
S. (2007). Multidisciplinary
management of brain metas-
tases. Oncologist 12, 884–898.
doi:10.1634/theoncologist.12-7-884
Ewend, M. G., Carey, L. A., Morris, D.
E., Harvey, R. D., and Hensing, T.
A. (2001). Brain metastases. Curr.
Treat. Options Oncol. 2, 537–547.
doi:10.1007/s11864-001-0075-8
Fagan, K. A., McMurtry, I. F., and
Rodman, D. M. (2001). Role of
endothelin-1 in lung disease. Respir.
Res. 2, 90–101. doi:10.1186/rr44
Falchook, G. S., Long, G. V.,
Kurzrock, R., Kim, K. B., Arke-
nau, T. H., Brown, M. P., et al.
(2012). Dabrafenib in patients with
melanoma, untreated brain metas-
tases, and other solid tumours: a
phase 1 dose-escalation trial. Lancet
379, 1893–1901. doi:10.1016/S0140-
6736(12)60398-5
Fazakas, C., Wilhelm, I., Nagyoszi, P.,
Farkas, A. E., Haskó, J., Molnár,
J., et al. (2011). Transmigra-
tion of melanoma cells through
the blood-brain barrier: role
of endothelial tight junctions
and melanoma-released serine
proteases. PLoS ONE 6:e20758.
doi:10.1371/journal.pone.0020758
Frontiers in Oncology | Cancer Genetics May 2013 | Volume 3 | Article 127 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gaziel-Sovran et al. Melanoma brain metastasis: models and mechanisms
Flaherty, K. T., Puzanov, I., Kim,
K. B., Ribas, A., McArthur, G.
A., Sosman, J. A., et al. (2010).
Inhibition of mutated, activated
BRAF in metastatic melanoma.
N. Engl. J. Med. 363, 809–819.
doi:10.1056/NEJMoa1002011
Fujimaki, T., Price, J. E., Fan, D.,
Bucana, C. D., Itoh, K., Kirino,
T., et al. (1996). Selective growth
of human melanoma cells in
the brain parenchyma of nude
mice. Melanoma Res. 6, 363–371.
doi:10.1097/00008390-199610000-
00003
Gast, A., Scherer, D., Chen, B., Bloeth-
ner, S., Melchert, S., Sucker, A.,
et al. (2010). Somatic alterations
in the melanoma genome: a high-
resolution array-based comparative
genomic hybridization study. Genes
Chromosomes Cancer 49, 733–745.
doi:10.1002/gcc.20785
Herlyn, M., Berking, C., Li, G., and
Satyamoorthy, K. (2000). Lessons
from melanocyte development for
understanding the biological events
in naevus and melanoma forma-
tion. Melanoma Res. 10, 303–312.
doi:10.1097/00008390-200008000-
00001
Hodi, F. S., Oble, D. A., Drappatz,
J., Velazquez, E. F., Ramaiya, N.,
Ramakrishna, N., et al. (2008).
CTLA-4 blockade with ipilimumab
induces significant clinical benefit
in a female with melanoma metas-
tases to the CNS. Nat. Clin. Pract.
Oncol. 5, 557–561. doi:10.1038/
ncponc1183
Hodi, F. S., O’Day, S. J., McDermott, D.
F., Weber, R. W., Sosman, J. A., Haa-
nen, J. B., et al. (2010). Improved
survival with ipilimumab in
patients with metastatic melanoma.
N. Engl. J. Med. 363, 711–723.
doi:10.1056/NEJMoa1003466
Huang, F. J., Steeg, P. S., Price, J. E.,
Chiu, W. T., Chou, P. C., Xie, K.,
et al. (2008). Molecular basis for
the critical role of suppressor of
cytokine signaling-1 in melanoma
brain metastasis. Cancer Res. 68,
9634–9642. doi:10.1158/0008-
5472.CAN-08-1429
Hwang, S. J., Seol, H. J., Park, Y. M.,
Kim, K. H., Gorospe, M., Nam, D. H.,
et al. (2012). MicroRNA-146a sup-
presses metastatic activity in brain
metastasis. Mol. Cells 34, 329–334.
doi:10.1007/s10059-012-0171-6
Isiklar, I., Leeds, N. E., Fuller, G. N.,
and Kumar, A. J. (1995). Intracra-
nial metastatic melanoma: correla-
tion between MR imaging charac-
teristics and melanin content. AJR
Am. J. Roentgenol. 165, 1503–1512.
doi:10.2214/ajr.165.6.7484597
Izraely, S., Klein, A., Sagi-Assif, O.,
Meshel, T., Tsarfaty, G., Hoon,
D. S., et al. (2010). Chemokine-
chemokine receptor axes in
melanoma brain metastasis.
Immunol. Lett. 130, 107–114.
doi:10.1016/j.imlet.2009.12.003
Izraely, S., Sagi-Assif, O., Klein, A.,
Meshel, T., Tsarfaty, G., Pasmanik-
Chor, M., et al. (2012). The
metastatic microenvironment:
brain-residing melanoma metastasis
and dormant micrometastasis.
Int. J. Cancer 131, 1071–1082.
doi:10.1002/ijc.27324
Johannessen, C. M., Boehm, J. S., Kim,
S. Y., Thomas, S. R., Wardwell, L.,
Johnson, L. A., et al. (2010). COT
drives resistance to RAF inhibi-
tion through MAP kinase pathway
reactivation. Nature 468, 968–972.
doi:10.1038/nature09627
Johnson, J. D., and Young, B. (1996).
Demographics of brain metasta-
sis. Neurosurg. Clin. N. Am. 7,
337–344.
Kienast, Y., von Baumgarten, L.,
Fuhrmann, M., Klinkert, W. E.,
Goldbrunner, R., Herms, J., et al.
(2010). Real-time imaging reveals
the single steps of brain metastasis
formation. Nat. Med. 16, 116–122.
doi:10.1038/nm.2072
Klein, A., Sagi-Assif, O., Izraely, S.,
Meshel, T., Pasmanik-Chor, M.,
Nahmias, C., et al. (2012). The
metastatic microenvironment:
brain-derived soluble factors alter
the malignant phenotype of cuta-
neous and brain-metastasizing
melanoma cells. Int. J. Cancer 131,
2509–2518. doi:10.1002/ijc.27552
Küsters, B., de Waal, R. M., Wesseling, P.,
Verrijp, K., Maass, C., Heerschap, A.,
et al. (2003). Differential effects of
vascular endothelial growth factor A
isoforms in a mouse brain metastasis
model of human melanoma. Cancer
Res. 63, 5408–5413.
Lee, B. C., Lee, T. H., Avraham,
S., and Avraham, H. K. (2004).
Involvement of the chemokine
receptor CXCR4 and its ligand
stromal cell-derived factor 1alpha
in breast cancer cell migration
through human brain microvascular
endothelial cells. Mol. Cancer Res. 2,
327–338.
Lee, I., Fox, P. S., Ferguson, S. D.,
Bassett, R., Kong, L. Y., Schacherer,
C. W., et al. (2012). The expres-
sion of p-STAT3 in stage IV
melanoma: risk of CNS metas-
tasis and survival. Oncotarget 3,
336–344.
Lin, Q., Balasubramanian, K., Fan, D.,
Kim, S. J., Guo, L., Wang, H., et al.
(2010). Reactive astrocytes protect
melanoma cells from chemother-
apy by sequestering intracellular cal-
cium through gap junction com-
munication channels. Neoplasia 12,
748–754.
Lonser, R. R., Song, D. K., Klapper,
J., Hagan, M., Auh, S., Kerr, P. B.,
et al. (2011). Surgical management
of melanoma brain metastases in
patients treated with immunother-
apy. J. Neurosurg. 115, 30–36.
doi:10.3171/2011.3.JNS091107
Ma, M. W., Qian, M., Lackaye, D.
J., Berman, R. S., Shapiro, R.
L., Pavlick, A. C., et al. (2012).
Challenging the current paradigm
of melanoma progression: brain
metastasis as isolated first visceral
site. Neuro-oncology 14, 849–858.
doi:10.1093/neuonc/nos113
Marchetti, D., Li, J., and Shen, R. (2000).
Astrocytes contribute to the brain-
metastatic specificity of melanoma
cells by producing heparanase. Can-
cer Res. 60, 4767–4770.
Margolin, K., Ernstoff, M. S., Hamid,
O., Lawrence, D., McDermott, D.,
Puzanov, I., et al. (2012). Ipili-
mumab in patients with melanoma
and brain metastases: an open-
label, phase 2 trial. Lancet Oncol.
13, 459–465. doi:10.1016/S1470-
2045(12)70090-6
Melero, I., Hervas-Stubbs, S., Glennie,
M., Pardoll, D. M., and Chen, L.
(2007). Immunostimulatory mon-
oclonal antibodies for cancer ther-
apy. Nat. Rev. Cancer 7, 95–106.
doi:10.1038/nrc2051
Morsi, A., Gaziel-Sovran, A., Cruz-
Munoz, W., Kerbel, R. S., Golfinos,
J. G., Hernando, E., et al. (2013).
Development and characterization
of a clinically relevant mouse model
of melanoma brain metastasis. Pig-
ment Cell Melanoma Res. (in press).
doi:10.1111/pcmr.12114
Murry, B. P., Blust, B. E., Singh, A.,
Foster, T. P., and Marchetti, D.
(2006). Heparanase mechanisms of
melanoma metastasis to the brain:
development and use of a brain slice
model. J. Cell. Biochem. 97, 217–225.
doi:10.1002/jcb.20714
Nazarian, R., Shi, H., Wang, Q., Kong,
X., Koya, R. C., Lee, H., et al.
(2010). Melanomas acquire resis-
tance to B-RAF(V600E) inhibition
by RTK or N-RAS upregulation.
Nature 468, 973–977. doi:10.1038/
nature09626
Padua, D., Zhang, X. H., Wang,
Q., Nadal, C., Gerald, W. L.,
Gomis, R. R., et al. (2008). TGF-
beta primes breast tumors for
lung metastasis seeding through
angiopoietin-like 4. Cell 133, 66–77.
doi:10.1016/j.cell.2008.01.046
Poulikakos, P. I., Persaud, Y., Janaki-
raman, M., Kong, X., Ng, C.,
Moriceau, G., et al. (2011). RAF
inhibitor resistance is mediated
by dimerization of aberrantly
spliced BRAF(V600E). Nature 480,
387–390. doi:10.1038/nature10662
Salvati, M., Frati, A., D’Elia, A., Pesca-
tori, L., Piccirilli, M., Pietrantonio,
A., et al. (2012). Single brain metas-
tases from melanoma: remarks on a
series of 84 patients. Neurosurg. Rev.
35, 211–217. doi:10.1007/s10143-
011-0348-z discussion 217-218,
Sampson, J. H., Carter, J. H. Jr., Fried-
man, A. H., and Seigler, H. F.
(1998). Demographics, prognosis,
and therapy in 702 patients with
brain metastases from malignant
melanoma. J. Neurosurg. 88, 11–20.
doi:10.3171/jns.1998.88.1.0011
Schartz, N. E., Farges, C., Made-
laine, I., Bruzzoni, H., Calvo, F.,
Hoos, A., et al. (2010). Com-
plete regression of a previously
untreated melanoma brain metas-
tasis with ipilimumab. Melanoma
Res. 20, 247–250. doi:10.1097/CMR.
0b013e3283364a37
Segura, M. F., Greenwald, H. S., Han-
niford, D., Osman, I., and Her-
nando, E. (2012). MicroRNA and
cutaneous melanoma: from dis-
covery to prognosis and ther-
apy. Carcinogenesis 33, 1823–1832.
doi:10.1093/carcin/bgs205
Stoletov, K., Strnadel, J., Zardouzian,
E., Momiyama, M., Park, F. D., Kel-
ber, J. A., et al. (2013). Role of
connexins in metastatic breast can-
cer and melanoma brain coloniza-
tion. J. Cell. Sci. 126(Pt 4), 904–913.
doi:10.1242/jcs.112748
Straume, O., Smeds, J., Kumar, R.,
Hemminki, K., and Akslen, L. A.
(2002). Significant impact of pro-
moter hypermethylation and the 540
C>T polymorphism of CDKN2A
in cutaneous melanoma of the ver-
tical growth phase. Am. J. Pathol.
161, 229–237. doi:10.1016/S0002-
9440(10)64174-0
Sundstrøm, T., Daphu, I., Wendelbo,
I., Hodneland, E., Lunder-
vold, A., Immervoll, H., et al.
(2013). Automated tracking of
nanoparticle-labeled melanoma
cells improves the predictive
power of a brain metastasis
model. Cancer Res. 73, 2445–2456.
doi:10.1158/0008-5472.CAN-12-
3514
Tekle, C., Nygren, M. K., Chen, Y. W.,
Dybsjord, I., Nesland, J. M., Mae-
landsmo, G. M., et al. (2012). B7-H3
contributes to the metastatic capac-
ity of melanoma cells by modula-
tion of known metastasis-associated
www.frontiersin.org May 2013 | Volume 3 | Article 127 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gaziel-Sovran et al. Melanoma brain metastasis: models and mechanisms
genes. Int. J. Cancer 130, 2282–2290.
doi:10.1002/ijc.26238
Thompson, J. F., Kroon, B. B. R., and
Morton, D. L. (2004). Textbook of
Melanoma. London: Martin Dunitz.
Weiss, L. (1992). Comments on
hematogenous metastatic patterns
in humans as revealed by autopsy.
Clin. Exp. Metastasis 10, 191–199.
doi:10.1007/BF00132751
Wilhelm, I., Fazakas, C., and Krizbai,
I. A. (2011). In vitro models of the
blood-brain barrier. Acta Neurobiol.
Exp. (Wars) 71, 113–128.
Xie, T. X., Huang, F. J., Aldape, K.
D., Kang, S. H., Liu, M., Gershen-
wald, J. E., et al. (2006). Activation
of stat3 in human melanoma pro-
motes brain metastasis. Cancer Res.
66, 3188–3196. doi:10.1158/0008-
5472.CAN-05-2674
Yano, S., Shinohara, H., Herbst, R. S.,
Kuniyasu, H., Bucana, C. D., Ellis,
L. M., et al. (2000). Expression
of vascular endothelial growth fac-
tor is necessary but not suffi-
cient for production and growth
of brain metastasis. Cancer Res. 60,
4959–4967.
Zakrzewski, J., Geraghty, L. N., Rose,
A. E., Christos, P. J., Mazum-
dar, M., Polsky, D., et al. (2011).
Clinical variables and primary
tumor characteristics predictive of
the development of melanoma
brain metastases and post-brain
metastases survival. Cancer 117,
1711–1720. doi:10.1002/cncr.25643
Zhang, L., Sullivan, P. S., Goodman, J.
C., Gunaratne, P. H., and Marche-
tti, D. (2011). MicroRNA-1258 sup-
presses breast cancer brain metasta-
sis by targeting heparanase. Cancer
Res. 71, 645–654. doi:10.1158/0008-
5472.CAN-10-1910
Zhang, X. H., Wang, Q., Gerald,
W., Hudis, C. A., Norton, L.,
Smid, M., et al. (2009a). Latent
bone metastasis in breast can-
cer tied to Src-dependent survival
signals. Cancer Cell 16, 67–78.
doi:10.1016/j.ccr.2009.05.017
Zhang, C., Zhang, F., Tsan, R., and
Fidler, I. J. (2009b). Transforming
growth factor-beta2 is a molecular
determinant for site-specific
melanoma metastasis in the
brain. Cancer Res. 69, 828–835.
doi:10.1158/0008-5472.CAN-08-
2588
Zhu, D. Z., Cheng, C. F., and Pauli,
B. U. (1991). Mediation of lung
metastasis of murine melanomas
by a lung-specific endothelial cell
adhesion molecule. Proc. Natl.
Acad. Sci. U.S.A. 88, 9568–9572.
doi:10.1073/pnas.88.21.9568
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 31 January 2013; accepted: 06
May 2013; published online: 31 May
2013.
Citation: Gaziel-Sovran A, Osman I and
Hernando E (2013) In vivo modeling
and molecular characterization: a path
toward targeted therapy of melanoma
brainmetastasis. Front.Oncol.3:127. doi:
10.3389/fonc.2013.00127
This article was submitted to Frontiers in
Cancer Genetics, a specialty of Frontiers
in Oncology.
Copyright© 2013Gaziel-Sovran,Osman
and Hernando. This is an open-access
article distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are cred-
ited and subject to any copyright notices
concerning any third-party graphics etc.
Frontiers in Oncology | Cancer Genetics May 2013 | Volume 3 | Article 127 | 8
